12.68% -0.0932

Avenue Therapeutics Inc (ATXI)

개요 뉴스 가격 이력 Financials ATXI 왜 하락? 토론 예측 주식 분할

Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc 주식(ATXI)의 최신 뉴스

NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World

Avenue Therapeutics, Inc.Common Stock (NQ: ATXI - FinancialContent

Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда

Axsome Therapeutics stock hits all-time high at 152.98 USD - Investing.com

Axsome Therapeutics stock hits all-time high at 152.98 USD By Investing.com - Investing.com Australia

Axsome Therapeutics (AXSM) Gets a Buy from Jefferies - The Globe and Mail

Avenue Therapeutics (ATXI) plans resale of 731,061 warrant-linked shares - Stock Titan

[RW] AVENUE THERAPEUTICS, INC. SEC Filing - Stock Titan

TG Therapeutics (NASDAQ:TGTX) Rating Increased to Buy at Wall Street Zen - MarketBeat

RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat

Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech

Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade

Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat

Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan

Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - WV News

Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com Canada

Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com

Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech

Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - WV News

Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits

Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo

Axsome Therapeutics stock reaches all-time high of 152.94 USD By Investing.com - Investing.com Australia

Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo

Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo

Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo

Axsome Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com

Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail

[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan

Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo

Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo

Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Nigeria

Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times

Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks

[10-Q] AVENUE THERAPEUTICS, INC. Quarterly Earnings Report | ATXI SEC FilingForm 10-Q - Stock Titan

Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo

ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo

Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo

Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN

ATXI과 유사한 종목